Study to Evaluate the AIO-001 in Healthy Participants
Status:
Active, not recruiting
Trial end date:
2024-12-20
Target enrollment:
Participant gender:
Summary
This goal of the open-label single dose study is to evaluate and compare the safety,
tolerability, pharmacokinetic (PK), and immunogenicity of AIO-001 using two different
formulations in 16 healthy volunteers.